key: cord-0970003-gc2oihxi
authors: Sogono, Paolo; Bressel, Mathias; David, Steven; Shaw, Mark; Chander, Sarat; Chu, Julie; Plumridge, Nikki; Byrne, Keelan; Hardcastle, Nick; Kron, Tomas; Wheeler, Greg; Hanna, Gerard G.; MacManus, Michael; Ball, David; Siva, Shankar
title: Safety, efficacy and patterns of failure after single fraction stereotactic body radiotherapy (SBRT) for oligometastases
date: 2020-10-15
journal: Int J Radiat Oncol Biol Phys
DOI: 10.1016/j.ijrobp.2020.10.011
sha: b428875cd912c8835a991c34df669401be0a4216
doc_id: 970003
cord_uid: gc2oihxi

Purpose Fewer attendances for radiotherapy results in increased efficiency and less foot traffic within a radiotherapy department. We investigated outcomes after single fraction (SF) SBRT in patients with oligometastatic disease. Methods and Materials Between February 2010 and June 2019, patients who received SF SBRT to 1-5 sites of oligometastatic disease were included in this retrospective study. The primary objective was to describe patterns of first failure after SBRT. Secondary objectives included overall survival (OS) progression-free survival (PFS), high-grade treatment-related toxicity (≥grade 3 CTCAE) and freedom from systemic therapy (FFST). Results In total, 371 patients with 494 extracranial oligometastases received SF SBRT ranging from 16Gy to 28Gy. The most common primary malignancies were prostate (n=107), lung (n=63), kidney (n=52), gastrointestinal (n=51), and breast cancers (n = 42). The median follow-up was 3.1 years. The 1, 3 and 5 year OS was 93%, 69% and 55%, respectively, PFS was 48%, 19% and 14%, respectively, and FFST was 70%, 43% and 35%, respectively. Twelve patients (3%) developed grade 3-4 treatment-related toxicity, with no grade 5 toxicity. As the first site of failure, the cumulative incidence of local failure (irrespective of other failures) at 1, 3 and 5-years was 4%, 8% and 8%, locoregional relapse at the primary was 10%, 18% and 18%, and distant failure was 45%, 66% and 70%, respectively. Conclusions SF SBRT is safe, effective, and a significant proportion of patients remain FFST for several years after therapy. This approach could be considered in resource constrained or bundled payment environments. Locoregional failure of the primary site is the second most common pattern of failure, suggesting a role for optimization of primary control during metastasis-directed therapy.

The COVID-19 pandemic has necessitated a sharp focus on delivering radiotherapy more efficiently in a resource-constrained environment. Efforts to limit traffic within a radiotherapy department have encouraged shortening of treatment courses [1, 2] . A recent European Society for Radiotherapy and Oncology (ESTRO) -American Society for Radiation Oncology (ASTRO) consensus statement showed strong consensus (90%) support for single-fraction (SF) 30-34Gy for stage I non-small cell lung cancer (NSCLC) if choosing increased hypofractionation during the pandemic [3] . Whilst SF stereotactic body radiotherapy (SBRT) for primary NSCLC has randomized phase II evidence to support consensus [4, 5] , evidence on choice of fractionation schedules for oligometastatic disease is lacking. However, if proven to be safe and effective, SF SBRT for oligometastatic disease may be particularly attractive during this global pandemic, and possibly beyond, especially in resource constrained or bundled payment environments. The purpose of this study is to assess clinical outcomes secondary to SF SBRT to 1-5 sites in patients with oligometastatic disease.

In particular, this study focuses on patterns of failure in order to inform strategies to optimize outcomes after SF SBRT to oligometastatic disease.

This retrospective study received institutional ethics board approval and assessed patients treated between February 2010 and June 2019 at the [BLINDED FOR REVIEW]. Eligible patients had solid-organ malignancies with metastatic disease, aged ≥18 years, and were treated with SF SBRT to 1-5 sites of disease. This research followed the STROBE guideline for reporting of cohort studies. Technical aspects of treatment delivery have been previously described [6] . Briefly, for tumors moving with respiration, a 4DCT was acquired for treatment planning which was used to define an internal target volume (ITV). Otherwise, a 3DCT was acquired for treatment planning on which a GTV was delineated. The CTV was considered equivalent to the GTV. A 5 mm GTV, CTV or ITV to planning target volume Alto, USA). Image guidance was performed using cone-beam CT, matching to the GTV/CTV/ITV with translation corrections only. For bone and vertebral body lesions stereoscopic x-rays were used in addition to cone-beam CT, with translation and rotation corrections applied.

Prior treatment for metastatic disease was not an exclusion criterion. Consecutive patients were included, and during the study period the most common reasons for receipt of multifraction SBRT was re-irradiation SBRT, spinal lesions with SINS score > 7, and liver metastases. Patients who had distant progression after SBRT with one to five metastases were routinely considered for further salvage SBRT. Patients with unknown primary malignancy or intracranial disease only were excluded. The primary objective was to describe patterns of first failure after SBRT. Secondary objectives were to assess patterns of failure after salvage The pattern of first failure is defined as the cumulative incidence of the first failure, considering each failure separately and was classified as local, locoregional (LR) of primary, or distant (and any combination of those failures). LR of primary is a failure in the primary site or in the regional draining lymph nodes related to the primary. For example, LR in the context of prostate cancer was defined as non-inguinal pelvic lymph nodes below the J o u r n a l P r e -p r o o f bifurcation, LR in the context of lung cancer was defined as mediastinal or ipsilateral supraclavicular lymph nodes. Attribution of local failure was clinician defined, and based on imaging findings with or without biopsy confirmation. Patients with prostate cancer and biochemical progression without radiological progression were censored at the date of biochemical progression for all analyses of recurrence. The Kaplan-Meier method was used to describe the time-to-event curves. Cumulative incidence curves assuming competing risks were provided to describe the pattern of first failure. A sensitivity analysis was performed assessing the cohort excluding patients with prostate cancer, secondly including only patients with prostate cancer, and again including only patients with lung cancer. All statistical analyses were performed in R (R version 3.6.1).

In total, 371 consecutive patients had 494 oligometastases treated with SF SBRT. The most common primary malignancies were prostate (29%), lung (17%), non-prostate genitourinary (14%), gastrointestinal (14%), and breast (11%) ( Table 1) . Sixty-four percent (n=238) had adenocarcinoma. For prior treatments, 96% received definitive treatment of the primary (e.g. surgery or radiotherapy); 33% had prior adjuvant or concurrent systemic therapy with the primary intervention, 24% had prior systemic therapy directed at metastatic disease, and 33% had systemic therapy at the time of SBRT. Twenty-eight percent received prior metastasisdirected therapy (MDT). At the time of SBRT, 96% had 1-3 active metastases. Of 494 lesions, 38% were in lung, 28% in bone, 16% in spine, and 11% in lymph nodes. Of the lung metastases, 10 (6%) were centrally located, and 157 (94%) were peripherally located. The prescription dose ranged from 16Gy to 28Gy and the most common prescription was 20Gy (58%). The mean (± standard deviation) metastasis size (maximal axial tumor dimension) was 20.4mm (± 14.7mm). Additional information about target characteristics and dose selection are found in Supplementary Table 2. In general, target dose selection was 16Gy-18Gy for complex bone or central lung, 20Gy-24Gy for bone or soft tissue, 26Gy-28Gy for adrenal and peripheral lung.

The median follow-up time was 3.1 years. Time to event outcomes are described in Table 2 .

Median OS was 5.4 years and 5-year OS was 55% (95% CI: 48-62) for the entire cohort.

Median PFS after SBRT was 1 year with a 5-year PFS rate of 14% (95% CI: 9-20). Median widespread failure-free survival was 2 years. Of the 252 patients who were not on systemic therapy at time of SBRT, median time to initiation of systemic therapy was 2.1 years, and 35% (95% CI: 26-43) were free from systemic therapy (FFST) at 5 years. Figure 1 depicts Kaplan-Meier estimates for survival outcomes of interest.

As prostate cancer can progress biochemically without radiological confirmation, and thereby systemic hormonal manipulation can be initiated before radiological progression, a sensitivity analysis was performed excluding prostate primaries. In this subset, OS, PFS and WFFS at 5 years was 43%, 12%, and 22% respectively. The median OS, PFS and WFFS were lower at 4 years, 0.8 years, and 1.6 years respectively. The median FFST of patients excluding prostate cancer was higher at 3.5 years. Analysis of the prostate cancer only subset of patients only revealed OS, PFS and WFFS at 5 years was 78%, 19%, and 30% respectively. While the subset including only lung cancer patients (the second largest primary malignancy group), the OS, PFS and WFFS at 5 years was 27%, 0%, and 11% respectively.

Patterns of first failure are summarized in Table 3 Sixty-one percent (n=228) of the patients did not report treatment-related toxicity. A total of 12 patients (3%) developed grade 3 or 4 treatment-related toxicity. One patient developed unexplained severe dyspnea without radiographic evidence of pneumonitis one month after SBRT to four peripheral lung metastases. One patient developed L5-S1 radiculopathy manifesting as foot-drop 43 months after 20Gy in 1 fraction to an L5 spine metastasis from sarcoma. The remaining high-grade toxicities were symptomatic fractures from treatment of bone (n = 6) or spine (n = 4) lesions. Of these 10, 4 had prior local treatments to the same site, either with surgery or radiotherapy. No treatment-related death (grade 5) was observed.

A cornerstone recommendation for radiotherapy during the COVID-19 pandemic has been the rationalization of fractionation schedules [2, 11, 12] . Our study findings suggest that SF SBRT for oligometastatic disease can be delivered with high local control and low toxicity. Iyengar et al. [19] in the context of lung cancer. In these early terminated studies of n=49 and n=29 patients, metastasis-directed therapy was used after initial induction systemic therapy.

The median PFS between the control and experimental arm was 4.4 months versus 14.2 month (p = 0.02), and 3.5 months versus 9.7 months (p = 0.01), respectively.

Interestingly, after distant recurrence we found that locoregional relapse in the primary was the second most common pattern of failure. Primary failures are rarely reported in studies describing outcomes following local oligometastases management, where failure in the primary is commonly classified as a distant failure. The reason may be the questionable clinical significance particularly in the setting of widespread metastatic disease. Although distant relapses predominate in the oligometastatic setting, it appears that primary relapses remain unavoidable. Chance et al. [20] reported 3 of 43 patients' primary site failed after SBRT to adrenal metastases (7% failure rate). Yoshida et al. [21] reported that 9 of 27 patients developed eventual primary relapse in the prostate (33% failure rate) after metastasis-directed therapy. Focusing on the primary is increasingly relevant because emerging evidence suggests that local treatment of the primary disease confers survival benefits in the metastatic setting [12, 22] . Most notably, in the STAMPEDE trial [22] , patients with low-volume metastatic prostate cancer had significantly improved survival upon receipt of prostate radiotherapy (HR 0.68). In our study, we observed an 18% risk of first failure being locoregional to the primary at 5 years, which suggests that there may be a role of optimizing control of the primary when planning metastasis directed therapy.

The classic phenotype of isolated oligometastatic disease potentially amenable to curative local treatment is, unfortunately, the exception rather than the rule in published literature. At 5 years, only a small minority (14%) would be free from any progression [13] and only 18-26% free from widespread metastasis in 5 years [14, 15] . This is consistent with our observations where 5-year PFS and WFFS was 14% and 24% respectively. Therefore, despite local efficacy, distant failure is common after SBRT in this cohort, which raises the question; is SBRT is a worthwhile intervention in the first instance? Perhaps an aspect that encourages J o u r n a l P r e -p r o o f a trial of the approach is the palatable adverse event profile of SF SBRT. We reported a relatively low rate of grade 3 to 4 toxicity (n = 12, 3%). In the context of a median time to initiation of systemic therapy of 2.1 years in the entire cohort, and 3.5 years in the cohort excluding prostate cancer patients, there is considerable potential for SBRT to preserve quality of life for clinically meaningful periods of time. There is also consistently reported a small minority of patients who remain disease free for years after SBRT, and when this outcome is realised and contextualised against the small impost of a single outpatient visit for treatment, SF SBRT may become a reasonably attractive proposition.

This study was limited by its retrospective nature and the inherent biases, including retrospective reporting of toxicity. Toxicity outcomes secondary to SBRT as compared to those secondary to medical comorbidities or other treatment modalities were difficult to differentiate. Attribution of local failure can be challenging and sometimes overestimated on radiology after SBRT and is a known limitation of patterns of failure analyses. There was heterogeneity in the patient cohort that limits interpretation of histology specific outcomes.

Whilst we included consecutive patients, these findings are from a single institution and are not externally validated.

Single-fraction SBRT is safe, effective, and a l l lll l l l l ll l l l l l l l l l ll l l l l l l l l l l l ll l l l l l l l l l l l l l ll l l l l l l l l l l l l l l ll l l l l l l l l l l l l l l l l l l l l l l l l l l ll ll l l l l l l l l l l l ll l l l l l l l l l l l l l l l ll l l l l l l ll l l l ll ll l l l l l l l l ll l l l ll l l l l l l l l lll l l l l lll l ll llll l l l ll l l ll l l l l l l l l l lll l l l l l l l l 

Radiotherapy in the time of the Coronavirus pandemic: when less is better

Letter from Italy: First practical indications for radiation therapy departments during COVID-19 outbreak

Practice recommendations for lung cancer radiotherapy during the COVID-19 pandemic: An ESTRO-ASTRO consensus statement

One Versus Three Fractions of Stereotactic Body Radiation Therapy for Peripheral Stage I to II Non-Small Cell Lung Cancer: A Randomized, Multi-Institution, Phase 2 Trial

Long-term Follow-up on NRG Oncology RTOG 0915 (NCCTG N0927): A Randomized Phase 2 Study Comparing

Stereotactic Body Radiation Therapy Schedules for Medically Inoperable Patients With Stage I Peripheral Non-Small Cell Lung Cancer

Radiotherapy in the time of the Coronavirus pandemic: when less is better

Efficacy and Safety of Locoregional Radiotherapy With Chemotherapy vs Chemotherapy Alone in De Novo Metastatic Nasopharyngeal Carcinoma: A Multicenter Phase 3 Randomized Clinical Trial

Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial

Hypofractionated Stereotactic Radiotherapy for Non-breast or Prostate Cancer Oligometastases: A Tail of Survival Beyond 10 Years

Phenotype-Oriented Ablation of Oligometastatic Cancer with Single Dose Radiation Therapy

Classification for long-term survival in oligometastatic patients treated with ablative radiotherapy: A multi-institutional pooled analysis

Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial

Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non-Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study

Consolidative Radiotherapy for Limited Metastatic Non-Small-Cell Lung Cancer: A Phase 2 Randomized Clinical Trial

Stereotactic ablative radiotherapy for adrenal gland metastases: Factors influencing outcomes, patterns of failure, and dosimetric thresholds for toxicity

Patterns of failure after progressive sitedirected therapy in oligo-progressive castration-resistant prostate cancer

Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial

18 (14, 23) Any Distant (± Local or LR to primary) 45 (39, 50)

 4.7, NE) 1.0 (0.8, 1.2) 2.0 (1.6, 2.5)  2.1 (1.8, 3. 

J o u r n a l P r e -p r o o f Any Local (± Distant) 4 (2, 6) 6 (4, 9) 8 (5, 11) 8 (5, 11) 8 (5, 11)